Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 39

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 39
---
 • |     | successfully complete ongoing clinical trials and obtain regulatory approvals for our current and future product 
 candidates;                                                                                                      |

| • |     | identify new acquisition or in-licensing opportunities; |

| • |     | successfully identify new product candidates and advance those product candidates into pre-clinical studies and clinical trials; |

| • |     | raise additional funds when needed and on terms acceptable to us; |

| • |     | attract and retain experienced management and advisory teams; |

| • |     | add operational, financial and management information systems and personnel, including personnel to support 
 clinical, manufacturing and planned future commercialization efforts and operations;                        |

| • |     | launch commercial sales of our product candidates, whether alone or in collaboration with others; |

| • |     | initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities                             
 of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; |

24

| • |     | set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party 
 payors;                                                                                                      |

| • |     | achieve market acceptance of product candidates in the medical community and with third-party payors and 
 consumers; and                                                                                           |

| • |     | maintain, expand and protect our intellectual property portfolio. |

If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. Since our inception, we have incurred significant net losses, with net losses of $72.8 million and $114.3 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, we had an accumulated deficit of approximately $563.1 million and $490.2 million, respectively. For the foreseeable future, we expect to continue to incur significant expenses related to the commercialization of ZTlido, GLOPERBA and ELYXYB and the research and development of our product candidates, SEMDEXA, SP-103,and SP-104.We anticipate that our expenses will increase substantially due to any future trials related to SEMDEXA and SP-103and initiation of the Phase 2 clinical trial for SP-104.Consequently, we expect to incur substantial losses for the foreseeable future and may never become profitable. We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and